Advanced

Kardiovaskulär behandlingspotential. P2-receptorer viktiga för framtida läkemedel

Erlinge, David LU (1999) In Läkartidningen 96(21). p.2586-2589
Abstract
Several receptors activated by extracellular nucleotides (ATP, ADP, UTP and UDP) have recently been cloned. These P2 receptors mediate a multitude of cardiovascular effects such as positive inotropic effects in the heart, platelet aggregation, release of endothelial factors, growth stimulation of vascular smooth muscle cells, vasomotor effects and blood pressure regulation. The physiological and pathophysiological importance of P2 receptors is established, and the first P2 receptor antagonists (ticlopidine and clopidrogel) are already in clinical use as inhibitors of platelet aggregation in the prevention of ischaemic heart disease and stroke. The development of selective antagonists for other P2 receptor subtypes will lead to better... (More)
Several receptors activated by extracellular nucleotides (ATP, ADP, UTP and UDP) have recently been cloned. These P2 receptors mediate a multitude of cardiovascular effects such as positive inotropic effects in the heart, platelet aggregation, release of endothelial factors, growth stimulation of vascular smooth muscle cells, vasomotor effects and blood pressure regulation. The physiological and pathophysiological importance of P2 receptors is established, and the first P2 receptor antagonists (ticlopidine and clopidrogel) are already in clinical use as inhibitors of platelet aggregation in the prevention of ischaemic heart disease and stroke. The development of selective antagonists for other P2 receptor subtypes will lead to better understanding of cardiovascular disease processes and yield new therapeutic options. (Less)
Please use this url to cite or link to this publication:
author
organization
alternative title
Cardiovascular treatment potentials. P2 receptors important for future drugs
publishing date
type
Contribution to journal
publication status
published
subject
keywords
P2-receptorer, Hjärt-kärlmedel, Hjärt-kärlsjukdomar
in
Läkartidningen
volume
96
issue
21
pages
2586 - 2589
external identifiers
  • pmid:10388279
  • scopus:0033606182
ISSN
0023-7205
language
Swedish
LU publication?
yes
id
e64a5e00-8dc8-4d15-b39b-4a886ca260a5 (old id 1114832)
alternative location
http://ltarkiv.lakartidningen.se/artNo19533
date added to LUP
2008-07-07 09:08:14
date last changed
2017-01-01 06:56:37
@article{e64a5e00-8dc8-4d15-b39b-4a886ca260a5,
  abstract     = {Several receptors activated by extracellular nucleotides (ATP, ADP, UTP and UDP) have recently been cloned. These P2 receptors mediate a multitude of cardiovascular effects such as positive inotropic effects in the heart, platelet aggregation, release of endothelial factors, growth stimulation of vascular smooth muscle cells, vasomotor effects and blood pressure regulation. The physiological and pathophysiological importance of P2 receptors is established, and the first P2 receptor antagonists (ticlopidine and clopidrogel) are already in clinical use as inhibitors of platelet aggregation in the prevention of ischaemic heart disease and stroke. The development of selective antagonists for other P2 receptor subtypes will lead to better understanding of cardiovascular disease processes and yield new therapeutic options.},
  author       = {Erlinge, David},
  issn         = {0023-7205},
  keyword      = {P2-receptorer,Hjärt-kärlmedel,Hjärt-kärlsjukdomar},
  language     = {swe},
  number       = {21},
  pages        = {2586--2589},
  series       = {Läkartidningen},
  title        = {Kardiovaskulär behandlingspotential. P2-receptorer viktiga för framtida läkemedel},
  volume       = {96},
  year         = {1999},
}